PE20000243A1 - Nuevos derivados del acido dihidroxihexanoico - Google Patents

Nuevos derivados del acido dihidroxihexanoico

Info

Publication number
PE20000243A1
PE20000243A1 PE1999000071A PE00007199A PE20000243A1 PE 20000243 A1 PE20000243 A1 PE 20000243A1 PE 1999000071 A PE1999000071 A PE 1999000071A PE 00007199 A PE00007199 A PE 00007199A PE 20000243 A1 PE20000243 A1 PE 20000243A1
Authority
PE
Peru
Prior art keywords
ocyl
inflammed
dihydroxy
amide
benzyl
Prior art date
Application number
PE1999000071A
Other languages
English (en)
Inventor
John Charles Kath
Christopher Stanley Poss
Matthew Frank Brown
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20000243A1 publication Critical patent/PE20000243A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A ACIDOS DIHIDROXIHEXANOICOS DE FORMULA I, SIENDO 4(R)-CARBAMOIL-1(S)-(3-CLORO-BENCIL)-2(S),7-DIHIDROXI-7-METIL-OCTIL]-AMIDA DEL ACIDO QUINOXALINA-2-CARBOXILICO, (1S)-BENCIL-4(R)-CARBAMOIL-2(S),7-DIHIDROXI-7-METIL-OCTIL)-AMIDA DEL ACIDO 7,8-DIFLUOROQUINOLINA-3-CARBOXILICO, ENTRE OTROS. EL COMPUESTO I ES INHIBIDOR POTENTE Y SELECTIVO DE LA UNION DE PEPTIDO QUIMIOTACTICO (QUIMIOCINAS) MIP-1O A SU RECEPTOR CCR1 EN LAS CELULAS INFLAMATORIAS E INMUNOMODULADORAS COMO LEUCOCITOS Y LINFOCITOS Y PUEDE SER UTIL PARA TRATAR LA INFLAMACION, ENFERMEDADES AUTOINMUNES, AFECCIONES INFLAMATORIAS AGUDAS Y CRONICAS, AFECCIONES ALERGICAS, INFECCION ASOCIADA CON LA INFLAMACION, ENFERMEDADES VIRICAS, RECHAZO DE TRASPLANTE DE TEJIDOS, ATEROSCLEROSIS, RESTENOSIS, INFECCION POR HIV, ENFERMEDADES GRANULOMATOSAS
PE1999000071A 1998-02-05 1999-02-01 Nuevos derivados del acido dihidroxihexanoico PE20000243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05

Publications (1)

Publication Number Publication Date
PE20000243A1 true PE20000243A1 (es) 2000-04-07

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000071A PE20000243A1 (es) 1998-02-05 1999-02-01 Nuevos derivados del acido dihidroxihexanoico

Country Status (37)

Country Link
EP (1) EP1051405B1 (es)
JP (1) JP3693916B2 (es)
KR (1) KR100385529B1 (es)
CN (1) CN1177834C (es)
AP (1) AP992A (es)
AR (1) AR016175A1 (es)
AT (1) ATE337307T1 (es)
AU (1) AU752407B2 (es)
BG (1) BG104726A (es)
BR (1) BR9907655A (es)
CA (1) CA2320388C (es)
DE (1) DE69932920T2 (es)
DZ (1) DZ2717A1 (es)
EA (1) EA003137B1 (es)
ES (1) ES2268847T3 (es)
GT (1) GT199900011A (es)
HK (1) HK1034969A1 (es)
HR (1) HRP20000529B1 (es)
HU (1) HUP0100832A3 (es)
IL (1) IL137330A0 (es)
IS (1) IS5562A (es)
MA (1) MA26603A1 (es)
MY (1) MY133125A (es)
NO (1) NO20003965D0 (es)
NZ (1) NZ505724A (es)
OA (1) OA11448A (es)
PA (1) PA8467301A1 (es)
PE (1) PE20000243A1 (es)
PL (1) PL342817A1 (es)
SK (1) SK11262000A3 (es)
TN (1) TNSN99013A1 (es)
TR (1) TR200002248T2 (es)
TW (1) TW470744B (es)
UA (1) UA57824C2 (es)
WO (1) WO1999040061A2 (es)
YU (1) YU47100A (es)
ZA (1) ZA99873B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535358A (ja) * 1999-01-29 2002-10-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 移植片拒絶反応及び虚血−再灌流障害の予防方法
BR0013469B1 (pt) * 1999-08-20 2011-01-25 amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica.
KR20020072304A (ko) * 2000-02-04 2002-09-14 화이자 프로덕츠 인코포레이티드 헤테로사이클릭 아미드 유도체
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
BR0210519A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de adsorvatos de fármaco amorfo
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
BR0307344A (pt) 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
KR20050006256A (ko) * 2002-05-14 2005-01-15 화이자 프로덕츠 인크. 디히드록시헥산산 유도체, 이들의 중간체, 및 제조 방법
WO2003095439A1 (en) * 2002-05-14 2003-11-20 Pfizer Products Inc. Methods for manufacture of dihydro-furan-2-one derivatives
CA2494776A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Crystal forms of quinoxaline-2-carboxylic acid ¬4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl|-amide
RU2005103625A (ru) 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) Фармацевтические композиции полуупорядоченных лекарств и полимеров
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
ES2180600T3 (es) * 1994-10-19 2003-02-16 Novartis Ag Eteres de isosteros substrato de aspartato proteasa antivirales.
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
EP1051405B1 (en) 2006-08-23
ZA99873B (en) 2000-08-04
JP2002502839A (ja) 2002-01-29
DZ2717A1 (fr) 2003-09-01
AP992A (en) 2001-08-06
JP3693916B2 (ja) 2005-09-14
WO1999040061A3 (en) 1999-10-21
HRP20000529B1 (en) 2004-12-31
IS5562A (is) 2000-07-14
EP1051405A2 (en) 2000-11-15
NO20003965L (es) 2000-10-03
TR200002248T2 (tr) 2000-12-21
BR9907655A (pt) 2000-10-24
CN1290255A (zh) 2001-04-04
EA003137B1 (ru) 2003-02-27
KR100385529B1 (ko) 2003-05-27
NO20003965D0 (no) 2000-08-04
HK1034969A1 (en) 2001-11-09
WO1999040061A2 (en) 1999-08-12
GT199900011A (es) 2000-07-20
DE69932920D1 (de) 2006-10-05
AU752407B2 (en) 2002-09-19
YU47100A (sh) 2002-11-15
OA11448A (en) 2003-11-18
AR016175A1 (es) 2001-06-20
HRP20000529A2 (en) 2001-08-31
AP9901457A0 (en) 1999-03-31
PA8467301A1 (es) 2000-05-24
SK11262000A3 (sk) 2001-01-18
HUP0100832A3 (en) 2002-03-28
KR20010040684A (ko) 2001-05-15
PL342817A1 (en) 2001-07-02
CA2320388A1 (en) 1999-08-12
BG104726A (en) 2001-04-30
MA26603A1 (fr) 2004-12-20
AU1778999A (en) 1999-08-23
TW470744B (en) 2002-01-01
NZ505724A (en) 2003-02-28
TNSN99013A1 (fr) 2005-11-10
CA2320388C (en) 2005-05-03
DE69932920T2 (de) 2007-02-08
UA57824C2 (uk) 2003-07-15
HUP0100832A2 (hu) 2002-02-28
CN1177834C (zh) 2004-12-01
ES2268847T3 (es) 2007-03-16
EA200000741A1 (ru) 2001-02-26
MY133125A (en) 2007-10-31
IL137330A0 (en) 2001-07-24
ATE337307T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
PE20000243A1 (es) Nuevos derivados del acido dihidroxihexanoico
BR0315234A (pt) Derivados de indol como agonistas beta-2
EA200401600A1 (ru) Новые комплексы карбоксипроизводных пиридина и эфиров жирной кислоты и полигидроксиалканов
ES2079373T3 (es) Nuevas azetidinonas sustituidas como agentes antiinflamatorios y antidegenerativos.
BR9814957A (pt) Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
ES2113881T3 (es) Derivados y analogos de acido 2-desoxi-2,3-didehidro-n-acetil neuraminico y su utilizacion como agentes antivirales.
ES2069410T3 (es) Nuevos derivados del acido hidroxamico y n-hidroxiurea y su uso.
ES554580A0 (es) Procedimiento para preparar derivados de amidoindol y amidoindazol
ATE46539T1 (de) Cystein-verminderte muteine von interferon-beta, ihre herstellung, zusammensetzungen, die diese muteine enthalten sowie strukturgene, vektoren und organismen geeignet zur verwendung bei der herstellung der genannten muteine und deren herstellung.
ES2161666T1 (es) Composiciones de xilitol para tratar estados de las vias respiratorias superiores.
BR8504138A (pt) Processo para produzir compostos heterociclicos tendo atividade para matar ervas daninhas,processo para obtencao de uma composicao herbicida,e composicao herbicida
PT1204650E (pt) Compostos de 2-arilbenzazole substituido e sua utilizacao como agentes antitumorais.
FI874839A0 (fi) Nya substituerade kefalosporinsulfoner anvaendbara som antiinflammatoriska och antidegenerativa medel.
ECSP045219A (es) Derivados de quinazolinona y su uso como agonistas cb
ES2157862B1 (es) Adicion a la patente principal numero 9902364 con titulo "nuevas actividades farmacologicas de los extractos del curcuma longa"
PE35196A1 (es) Derivado de benzamidina util como antagonista de ltb4
BRPI0506694A (pt) análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
MX9203409A (es) Proteinas bcrfi como inhibidores de la gama interferona.
UY27662A1 (es) Inhibidores de la mocroglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny.
TR200103004T2 (tr) Pirolidinkarbonilamino siklik disülfitler.
ES2061218T3 (es) Composiciones farmaceuticas estabilizadas.
AR009133A1 (es) Un procedimiento para preparar 5,6-dimetil-2-(4-fluorofenilamino)-4-(1-metil- 1,2,3,4-tetrahidroisoquinolin-2-il)pirimidina, procedimientos para preparar una 4-halogeno-2-(4-fluorofenilamino)-5,6-dimetilpirimidina y un derivado de pirimidina util como intermediario
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
ES2053478T3 (es) Proceso mejorado para preparar 2,4-quinazolinodiaminas 5,6-substituidas y nuevos intermedios.
EA200101096A1 (ru) Применение производных мадурафталазина в качестве ингибиторов провоспалительных цитокинов

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed